← Product Code [OZE](/submissions/MI/subpart-d%E2%80%94serological-reagents/OZE) · K161556 # CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit (K161556) _Centers For Disease Control and Prevention (CDC) · OZE · Jun 30, 2016 · Microbiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/OZE/K161556 ## Device Facts - **Applicant:** Centers For Disease Control and Prevention (CDC) - **Product Code:** [OZE](/submissions/MI/subpart-d%E2%80%94serological-reagents/OZE.md) - **Decision Date:** Jun 30, 2016 - **Decision:** SESE - **Submission Type:** Special - **Regulation:** 21 CFR 866.3980 - **Device Class:** Class 2 - **Review Panel:** Microbiology ## Indications for Use The Influenza A Subtyping Kit contains reagents and controls of the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel and is intended for use in real-time RT-PCR (rRT-PCR) assays on an Applied Biosystems (ABI) 7500 Fast Dx Real-Time PCR instrument in conjunction with clinical and epidemiological information: · For determination of the subtype of seasonal human influenza A viruses as seasonal A(H3), and/or A(H1)pdm09 from viral RNA in upper respiratory tract clinical specimens (including nasopharyngeal swabs [NPS], nasal swabs [NS], throat swabs [TS], nasal aspirates [NA], nasal washes [NW] and dual nasopharyngeal/throat swabs [NPS/TS]) and lower respiratory tract specimens (including bronchoalveolar lavage [BAL], bronchial wash [BW], tracheal aspirate [TA], sputum, and lung tissue) from human patients with signs and symptoms of respiratory infection and/or from viral culture; · To provide epidemiologic information for surveillance of circulating influenza viruses. ## Device Story The CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit (VER 2) is an in vitro diagnostic assay for the qualitative detection and characterization of influenza A virus RNA. It utilizes real-time RT-PCR (rRT-PCR) on the Applied Biosystems 7500 Fast Dx Real-Time PCR instrument. The kit includes oligonucleotide primers and fluorescently labeled hydrolysis probes targeting conserved regions of the influenza A matrix (M) gene, nucleoprotein (NP) gene, and HA genes for A(H3) and A(H1)pdm09 subtyping. It also detects human RNase P as an internal control. The device is used in clinical and public health laboratories by trained personnel. Results are interpreted in conjunction with clinical and epidemiological data to aid in influenza surveillance and patient management. The updated version incorporates modified primers and probes for the pdmH1 assay to improve reactivity with the 6B.1 genetic clade and utilizes ZEN double-quenched probe technology. The H1 assay has been removed as it is no longer clinically necessary. ## Clinical Evidence Retrospective study using archived clinical specimens (2011-2016). Evaluated 42 specimens positive for A(H1)pdm09 (including those with aberrant results in previous assay) and 32 specimens positive for A(H3). Compared modified assays against predicate/sequence analysis. Results showed high positive percent agreement (97.1-100% for A(H1)pdm09; 100% for A(H3)) and 100% negative percent agreement across tested specimen types (NPS, NS, NW, TS, BW, NA). ## Technological Characteristics The device uses rRT-PCR technology with oligonucleotide primers and fluorescent hydrolysis probes (ZEN double-quenched or BHQ-1). It targets influenza A matrix, nucleoprotein, and HA genes. It is designed for use on the Applied Biosystems 7500 Fast Dx Real-Time PCR instrument. It requires RNA extraction using cleared methods (e.g., QIAamp DSP Viral RNA Mini Kit, MagNA Pure, NucliSENS easyMAG) and specific enzyme master mixes (Invitrogen SuperScript III or Quanta qScript). ## Regulatory Identification A respiratory viral panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple viral nucleic acids extracted from human respiratory specimens or viral culture. The detection and identification of a specific viral nucleic acid from individuals exhibiting signs and symptoms of respiratory infection aids in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory findings. The device is intended for detection and identification of a combination of the following viruses:(1) Influenza A and Influenza B; (2) Influenza A subtype H1 and Influenza A subtype H3; (3) Respiratory Syncytial Virus subtype A and Respiratory Syncytial Virus subtype B; (4) Parainfluenza 1, Parainfluenza 2, and Parainfluenza 3 virus; (5) Human Metapneumovirus; (6) Rhinovirus; and (7) Adenovirus. ## Special Controls *Classification.* Class II (special controls). The special controls are:(1) FDA's guidance document entitled “Class II Special Controls Guidance Document: Respiratory Viral Panel Multiplex Nucleic Acid Assay;” (2) For a device that detects and identifies Human Metapneumovirus, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Human Metapneumovirus (hMPV) Using Nucleic Acid Assays;” and (3) For a device that detects and differentiates Influenza A subtype H1 and subtype H3, FDA's guidance document entitled “Class II Special Controls Guidance Document: Testing for Detection and Differentiation of Influenza A Virus Subtypes Using Multiplex Nucleic Acid Assays.” See § 866.1(e) for the availability of these guidance documents. ## Predicate Devices - CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit ([K140851](/device/K140851.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} SPECIAL 510(k): Device Modification OIR Decision Summary To: THE FILE RE: K161556 This 510(k) submission contains information/data on modifications made to the SUBMITTER'S own Class II device requiring 510(k). The following items are present and acceptable: 1. The name and 510(k) number of the SUBMITTER'S previously cleared device. Trade Name: CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit 510(k) Number: k140851 2. Submitter's statement that the INDICATION/INTENDED USE of the modified device, called "CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit VER2", as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, and package labeling. Submitter states in the labeling, 510(k) Summary, and in the submission that the intended use of the modified device has not changed from its predicate. 3. A description of the device MODIFICATIONS, including clearly labeled diagrams and assay instructions in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed. The modifications presented in this special 510k include: a) Redesign of the reverse primer and probe sequences for A/pdmH1N1 assay to better detect currently circulating influenza A(H1N1)pdm09 viruses belonging to the 6B.1 genetic clade; b) Evaluation of ZEN™ Double-Quenched probes (InfA-P, H3-P, pdmInfA-P, pdmH1-P, and RP-P) as an alternate option to the currently cleared BHQ probes; c) Elimination of the influenza A/H1 primers/probe (H1-F, H1-R, H1-P) set of reagents because this influenza virus is no longer circulating and the assay for its detection is unnecessary; d) Elimination of references and instructions for A/H1 from the IFU statement, package labels, software, and labeling; e) Replace positive control PIPC (inactive A/H1, A/H3, A/H1pdm09, B) with SPIC (inactive A/H3, A/H1pdm09, B); f) Updating nomenclature of influenza A virus subtypes to align with WHO nomenclature. Designations A/H1, A/H3 and A/H1pdm updated to A(H1N1), A(H3N2) and A(H1N1)pdm09; g) Updates to the device labeling: - Addition of study results demonstrating the performance of modified assays (modified primers and probes); - Replacing LoD data for influenza A/(H3/N2) strains A/New York/55/2004 and A/Wisconsin/67/2005 with data for A/Perth/16/2009 and A/Victoria/361/2011 strains; {1} Page 2 of 10 - Addition of reactivity data with potential pandemic influenza A swine H1N1v viruses A/Texas/14/2008, A/Ohio/09/2015, and A/Minnesota/19/2011; - Strains A/Maryland/12/1991 and A/Swine/Wisconsin/125/1997 were removed from the reactivity table as per sponsor indication that they no longer circulate; 4. Comparison Information (similarities and differences) to applicant's legally marketed predicate device including, labeling, intended use, physical characteristics, and software is shown in the table below. | Element | Predicate: CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel Diagnostic Panel, Influenza A Subtyping Kit (K140851) | Modified Device: CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel Diagnostic Panel, Influenza A Subtyping Kit (VER 2) (K161556) | | --- | --- | --- | | Intended Use | The Influenza A Subtyping Kit contains reagents and controls of the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel and is intended for use in real-time RT-PCR (rRT-PCR) assays on an Applied Biosystems (ABI) 7500 Fast Dx Real-Time PCR instrument in conjunction with clinical and epidemiological information: For determination of the subtype of seasonal human influenza A viruses as seasonal A/H1, A/H3, and/or A/H1pdm09 from viral RNA in upper respiratory tract clinical specimens (including nasopharyngeal swabs [NPS], nasal swabs [NS], throat swabs [TS], nasal aspirates [NA], nasal washes [NW] and dual nasopharyngeal/throat swabs [NPS/TS]) and lower respiratory tract specimens (including bronchoalveolar lavage [BAL], bronchial wash [BW], tracheal aspirate [TA], sputum, and lung tissue) from human patients with signs and symptoms of respiratory infection and/or from viral culture; To provide epidemiologic information for surveillance of circulating influenza viruses. Performance characteristics for influenza were established during a season when seasonal influenza viruses A/H1 and A/H3 were the predominant influenza A viruses in | The Influenza A Subtyping Kit contains reagents and controls of the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel and is intended for use in real-time RT-PCR (rRT-PCR) assays on an Applied Biosystems (ABI) 7500 Fast Dx Real-Time PCR instrument in conjunction with clinical and epidemiological information: For determination of the subtype of seasonal human influenza A viruses as seasonal A(H3), and/or A(H1)pdm09 from viral RNA in upper respiratory tract clinical specimens (including nasopharyngeal swabs [NPS], nasal swabs [NS], throat swabs [TS], nasal aspirates [NA], nasal washes [NW] and dual nasopharyngeal/throat swabs [NPS/TS]) and lower respiratory tract specimens (including bronchoalveolar lavage [BAL], bronchial wash [BW], tracheal aspirate [TA], sputum, and lung tissue) from human patients with signs and symptoms of respiratory infection and/or from viral culture; To provide epidemiologic information for surveillance of circulating influenza viruses. Performance characteristics for influenza were established during a season when seasonal influenza viruses A(H1N1) and A(H3N2) were the predominant influenza A viruses in circulation and during a season when | | | in the same region of the human influenza virus A/H1 and A/H3 and the same region of the human influenza virus A/H1pdm09 from viral RNA in the same region of the human influenza virus A/H1 and A/H3 and the same region of the human influenza virus A/H1 and A/H3 and the same region of the human influenza virus A/H1 and A/H3 and the same region of the human influenza virus A/H1 and A/H3 and the same region of the human influenza virus A/H1 and | in the same region of the human influenza virus A/H1 and A/H3 and the same region of the human influenza virus A/H1 and A/H3 and the same region of the human influenza virus A/H1 and A/H3 and the same region of the human influenza virus A/H1 and the same region of the human influenza virus A/H1 and the same region of the human influenza virus A/H1 and the same | {2} Page 3 of 10 | Element | Predicate: CDC Human Influenza Virus Real-Time RT- PCR Diagnostic Panel Diagnostic Panel, Influenza A Subtyping Kit (K140851) | Modified Device: CDC Human Influenza Virus Real-Time RT- PCR Diagnostic Panel Diagnostic Panel, Influenza A Subtyping Kit (VER 2) (K161556) | | --- | --- | --- | | | circulation and during a season when the A/H1pdm09 influenza virus was the predominant influenza A virus in circulation. Performance characteristics may vary with other emerging influenza A viruses. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other patient management decisions. Conversely, positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted unless a BSL 3+ facility is available to receive and culture specimens. Text box in IFU: All users, analysts, and any person reporting results from use of this device should be trained to perform and interpret the results from this procedure by a competent instructor prior to use. CDC Influenza Division will limit the distribution of this device to only those users who have successfully completed a training course provided by CDC instructors or designees. | the A(H1N1)pdm09 influenza virus was the predominant influenza A virus in circulation. Performance characteristics may vary with other emerging influenza A viruses. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other patient management decisions. Conversely, positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted unless a BSL 3E facility is available to receive and culture specimens. Text box in IFU: All users, analysts, and any person reporting results from use of this device should be trained to perform and interpret the results from this procedure by a competent instructor prior to use. CDC Influenza Division will limit the distribution of this device to only those users who have successfully completed a training course provided by CDC instructors or designees. | | Organism Detected | Universal influenza A viruses (animal and human), Swine-origin influenza A viruses, Influenza A subtypes: seasonal A(H1), A(H3), A(H1)pdm09 | Universal influenza A viruses (animal and human), Swine-origin influenza A viruses, Influenza A subtypes: seasonal A(H3) and A(H1)pdm09 | | Specimen Types | Nasopharyngeal swabs, nasal swabs, throat swabs, nasal aspirates, nasal | Same | 3 {3} Page 4 of 10 | Element | Predicate: CDC Human Influenza Virus Real-Time RT- PCR Diagnostic Panel Diagnostic Panel, Influenza A Subtyping Kit (K140851) | Modified Device: CDC Human Influenza Virus Real-Time RT- PCR Diagnostic Panel Diagnostic Panel, Influenza A Subtyping Kit (VER 2) (K161556) | | --- | --- | --- | | | washes and dual nasopharyngeal/throat swabs, bronchoalveolar lavages, bronchial aspirates, bronchial washes, tracheal aspirates, sputum, and lung tissue. | | | Nucleic Acid Extraction | Yes | Same | | Extraction Method | • QIAamp® DSP Viral RNA Mini Kit, Qiagen • MagNA Pure Compact –Nucleic Acid Isolation Kit I, Roche • MagNA Pure Compact – RNA Isolation Kit, Roche • MagNA Pure LC – Total Nucleic Acid Kit, Roche • Qiagen QIAcube – QIAamp® DSP Viral RNA Mini Kit, Qiagen • NucliSENS® easyMAG®, bioMerieux | Same | | Enzyme Master Mix | Invitrogen SuperScript™ III Platinum® One-Step Quantitative RT-PCR Kit (with or without ROX) OR Quanta BioSciences qScript™ One-Step qRT-PCR Kit, Low ROX | Same | | Technological Principles | Real-time RT-PCR | Same | | Instrumentation | Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument with SDS software version 1.4 | Same | | Probe Quenching Molecule | Black Hole Quencher Probe (BHQ-1) | ZEN Double-Quenched Probe (InfA, H3, pdmInfA, pdmH1, and RP assays) OR Black Hole Quencher Probe (InfA, H3, pdmInfA, pdmH1, and RP assays) | | Oligonucleotides | H1 Assay-Targets a region of the HA gene H3 assay-Targets a region of the HA gene pdmH1 assay-Targets a region of the HA gene InfA assay-Targets a conserved region of the matrix gene in Influenza A viruses | Gene targets of the oligonucleotide assays are the same as the predicate; minor changes to the pdmH1 oligonucleotide sequences have been made; the H1 assay is not included in this version of the Influenza A Subtyping Kit | 4 {4} Page 5 of 10 | Element | Predicate: CDC Human Influenza Virus Real-Time RT- PCR Diagnostic Panel Diagnostic Panel, Influenza A Subtyping Kit (K140851) | Modified Device: CDC Human Influenza Virus Real-Time RT- PCR Diagnostic Panel Diagnostic Panel, Influenza A Subtyping Kit (VER 2) (K161556) | | --- | --- | --- | | | pdmInfA-Targets a conserved region of the nucleoprotein gene in Influenza A(H1N1) pdm09 viruses | | 5. A Design Control Activities Summary was present which includes: a) Identification of Risk Analysis method used to assess the impact of the modification on the device and its components, and the results of the analysis The risk analysis for the CDC Influenza A Subtyping Kit was conducted to verify that the device modifications do not present increased or new risks to the user. The following potential risk factors were identified: 1) the modified oligonucleotides may demonstrate variable reactivity among virus strains, and 2) that labeling changes may result in testing errors leading to inaccurate or delayed assay results. Mitigations for risk #1 included analytical reactivity verification testing. For risk #2, the proposed mitigations are to distribute to the end users an updated labeling (package insert) for the Influenza A Subtyping Kit and a Product Update Communication explaining the modifications and communicating the availability of the updated Influenza A Subtyping Kit. Proposed mitigations should bring the identified hazards to an acceptable level. b) Based on the Risk Analysis, an identification of the verification activities required, including tests used and acceptance criteria to be applied. ## Verification of Performance The following studies were conducted to mitigate the risk of variable reactivity of the modified primers and probes: ## Analytical sensitivity A study was conducted to compare the approximate Limit of Detection (LoD; range finding study, n=3 per each analyte concentration) between cleared and modified RT-PCR reaction mixtures. The viruses tested were the historic virus A/California/07/2009 and the recent virus A/West Virginia/01/2016. The latter strain includes the point mutations that cause aberrant results with the current cleared A(H1)pdm09 assay. Characterized viruses of a known 50% infectious dose titer (EID50/mL or TCID50/mL) were extracted, and the RNA was serially diluted and tested in order to determine an estimated LoD (the lowest concentration where 3 of 3 replicates are detected). These studies were conducted with two RT-PCR enzyme systems cleared for use with the CDC Influenza A Sybtyping Kit (Invitrogen Superscript and Quanta qscript). The results of the range-finding LoD study indicate equivalent reactivity between the cleared and modified reaction mixtures for the historic virus A/California/07/2009. The results for A/West 5 {5} Page 6 of 10 Virginia/01/2016 confirm that the modified A(H1)pdm09 assay detects the virus bearing the point mutation that was not detected by the current A(H1)pdm09 assay. The estimated LoD was confirmed by testing extraction replicates (n=20) of the highest virus dilution (of the range-finding study) where greater than or equal to 95% of replicates tested positive. These studies were conducted with two RT-PCR enzyme systems cleared for use with the CDC Influenza A Sybtyping Kit (Invitrogen Superscript and Quanta qscript). The following lowest concentration where the InfA, pdmInfA, and pdmH1 primer and probe sets demonstrate uniform detection was reported as the LOD. | Influenza Virus Tested | Influenza Strain Designation | LoD (ID50/mL) | | | --- | --- | --- | --- | | | | Invitrogen SuperScript | Quanta qScript | | A(H1)pdm09 | A/West Virginia/01/2016 | 10^{0.9} | 10^{0.9} | | | A/California/07/2009 | 10^{3.1} | 10^{3.8} | A comparison study was conducted to demonstrate LOD equivalency for the A/H3 assays between the currently cleared BHQ probe and the ZEN probe. The RNA was extracted from A/Hong Kong/4801/2014 virus, was serially deluted, and three replicates per dilution were tested. The results indicate similar analytical sensitivity between the assays with ZEN and BHQ-1 probes. ## Inclusivity An inclusivity study was conducted to demonstrate the capability of the modified primer/probe RT-PCR mixtures (InfA, pdmInfA and pdmH1 with ZEN probes) to detect influenza A(H1)pdm09 viruses representative of different geographic locations and phylogenetic clades. Inclusivity testing was performed with ten representative H1pdm09 viruses at or near the established LoD. The viruses were grown to high titer, harvested, and serially diluted to near the LoD of the assays. The diluted viruses were extracted and tested (n=3 replicates) to demonstrate reactivity. The Influenza A Subtyping Kit was reactive with all H1pdm09 isolates tested. The inclusivity results are presented in the table below. | Influenza Virus Strain A(H1N1)pdm09 Identification | ID50/mL | | --- | --- | | A/California/04/2009 | 10^{2.9} | | A/California/07/2009 | 10^{3.5} | | A/Colorado/14/2012 | 10^{1.1} | | A/Florida/27/2011 | 10^{1.9} | {6} Page 7 of 10 | A/Florida/62/2014 | 10^{2.2} | | --- | --- | | A/Maryland/13/2012 | 10^{1.0} | | A/Minnesota/03/2011 | 10^{3.9} | | A/North Carolina/4/2014 | 10^{3.3} | | A/Utah/13/2016 | 10^{1.5} | | A/Washington/24/2012 | 10^{2.5} | ## Analytical Specificity Analytical specificity was evaluated by testing influenza A(H1) virus strains representing diverse geographic locations. Samples were tested in triplicate using RNA extracted from high titer preparations of viruses (≥ 10⁶ ID50/mL). Cross-reactivity testing was conducted with two enzyme systems (Invitrogen Superscript and Quanta qscript) and one extraction method cleared for use with the Influenza A Subtyping Kit. The results are presented in the table below. | Strain Designation Subtype | ID50/mL | SuperScript | | | qScript | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | InfA | pdm InfA | pdm H1 | InfA | pdm InfA | pdm H1 | | A/Brisbane/59/07 A(H1N1) | 10^{8.4} | (+) 3/3 | - | - | (+) 3/3 | - | - | | A/Hawaii/15/2001 A(H1N1) | 10^{8.1} | (+) 3/3 | - | - | (+) 3/3 | - | - | | A/Iowa/1/2006 A(H1N1v) | 10^{8.2} | (+) 3/3 | (+) 3/3 | (+) 3/3 | (+) 3/3 | (+) 3/3 | (+) 3/3 | | A/Texas/14/2008 A(H1N1v) | 10^{8.3} | (+) 3/3 | (+) 3/3 | (+) 3/3 | (+) 3/3 | (+) 3/3 | (+) 3/3 | | A/Ohio/09/2015 A(H1N1v) | 10^{7.7} | (+) 3/3 | (+) 3/3 | (+) 3/3 | (+) 3/3 | (+) 3/3 | (+) 3/3 | | A/Minnesota/19/2011 A(H1N2v) | 10^{7.1} | (+) 3/3 | (+) 3/3 | - | (+) 3/3 | (+) 3/3 | - | The reactivity data for three animal viruses, A/Texas/14/2008, A/Ohio/09/2015 and A/Minnesota/19/2011 were added to the reactivity table in the labeling. {7} Page 8 of 10 # Performance testing with archived clinical specimens The performance when testing clinical specimens was evaluated for the modified Influenza A Subtyping Kit (VER2) including all ZEN quencher probes and the pdmH1 reagents with modified reverse primer and probe sequences. A clinical specimen set was pre-selected from archives of past influenza seasons 2011-2012, 2013-2014 and 2015-2016. The specimens were characterized as positive or negative for influenza using the cleared predicate device or genetic sequence analysis. One group of specimens included forty-two specimens from the 2015-2016 influenza season that produced aberrant results with the current, cleared pdmH1 assay, but were confirmed to be positive with A(H1)pdm09 influenza virus by genetic sequence analysis. These specimens were tested to validate reactivity with the modified InfA, pdmInfA, and pdmH1 assays. A second group of thirty-two specimens, previously confirmed to be positive for A(H3) influenza virus, was tested to validate reactivity with the InfA, and H3 assays containing the $\mathsf{ZEN}^{\mathsf{TM}}$ double-quenched probe. A final group included specimens that were previously confirmed to be negative for influenza A by the cleared InfA assay. This testing was conducted with two enzyme systems (Invitrogen Superscript and Quanta qscript) and one extraction method cleared for use with the Influenza A Subtyping Kit. The results are summarized in the four tables below. Retrospective Positive Clinical Study Results-A(H1)pdm09 Comparison | | Invitrogen SuperScript | | Quanta qScript | | | --- | --- | --- | --- | --- | | Specimen Type | # of Positives | % Positive Agreement (95% CI) | # of Positives | % Positive Agreement (95% CI) | | BW | 1/1 | 100.0 | 1/1 | 100.0 | | NPS, NS | 34/35 | 97.1 (85.5-99.5) | 33/33 | 100.0 (89.6-100.0) | | NW | 4/4 | 100.0 (51.0-100.0) | 4/4 | 100.0 (51.0-100.0) | | TS | 2/2 | 100.00 (34.2-100.0) | 2/2 | 100.00 (34.2-100.0) | {8} Page 9 of 10 Retrospective Positive Clinical Study Results-A(H3) Comparison | | Invitrogen SuperScript | | Quanta qScript | | | --- | --- | --- | --- | --- | | Specimen Type | # of Positives | % Positive Agreement (95% CI) | # of Positives | % Positive Agreement (95% CI) | | NA | 1/1 | 100.0 (20.7-100.0) | 1/1 | 100.0 (20.7-100.0) | | NPS, NS | 30/30 | 100.0 (88.7-100.0) | 30/30 | 100.00 (88.7-100.00) | | NW | 1/1 | 100.0 (20.7-100.0) | 1/1 | 100.0 (20.7-100.0) | Retrospective Negative Clinical Study Results-A(H1)pdm09 Comparison | | Invitrogen SuperScript | | Quanta qScript | | | --- | --- | --- | --- | --- | | Specimen Type | # of Negatives | % Negative Agreement (95% CI) | # of Negatives | % Negative Agreement (95% CI) | | NPS | 53/53 | 100.00 (93.2-100.0) | 52/52 | 100.00 (93.1-100.0) | Retrospective Negative Clinical Study Results-A(H3) Comparison | | Invitrogen SuperScript | | Quanta qScript | | | --- | --- | --- | --- | --- | | Specimen Type | # of Negatives | % Negative Agreement (95% CI) | # of Negatives | % Negative Agreement (95% CI) | | NPS | 29/29 | 100.00 (88.3-100.0) | 28/28 | 100.00 (87.9-100.0) | The results demonstrate high positive and negative percent agreement between the cleared and the modified assays. {9} Page 10 of 10 6. Conclusion The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modifications and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared device. 10 --- **Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/OZE/K161556](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/OZE/K161556) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com